These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 23943181)
21. Nursing Roles in Cardiac Safety: Romidepsin in Patients With T-Cell Lymphoma. Hronek J; Reed M Oncol Nurs Forum; 2016 Mar; 43(2):227-34. PubMed ID: 26906133 [TBL] [Abstract][Full Text] [Related]
22. Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma. Kim EJ; Kim YH; Rook AH; Lerner A; Duvic M; Reddy S; Robak T; Becker JC; Samtsov A; McCulloch W; Waksman J; Whittaker S Leuk Lymphoma; 2015; 56(10):2847-54. PubMed ID: 25791237 [TBL] [Abstract][Full Text] [Related]
23. Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study. Dupuis J; Morschhauser F; Ghesquières H; Tilly H; Casasnovas O; Thieblemont C; Ribrag V; Bossard C; Le Bras F; Bachy E; Hivert B; Nicolas-Virelizier E; Jardin F; Bastie JN; Amorim S; Lazarovici J; Martin A; Coiffier B Lancet Haematol; 2015 Apr; 2(4):e160-5. PubMed ID: 26687958 [TBL] [Abstract][Full Text] [Related]
24. Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Woo S; Gardner ER; Chen X; Ockers SB; Baum CE; Sissung TM; Price DK; Frye R; Piekarz RL; Bates SE; Figg WD Clin Cancer Res; 2009 Feb; 15(4):1496-503. PubMed ID: 19228751 [TBL] [Abstract][Full Text] [Related]
25. Romidepsin in relapsed/refractory T-cell lymphomas: Italian experience and results of a named patient program. Zinzani PL; Pellegrini C; Cerciello G; Monaco F; Volpetti S; Peli A; Angelucci E; Corradini P; Cox MC; Guarini A; Musso M; Bresciani P; Amato G; Billio A; Caparrotti G; Figuera A; Nassi L; Gaudio F; Grossi A; Onida F; Merli M; Rigacci L; Argnani L Leuk Lymphoma; 2016 Oct; 57(10):2370-4. PubMed ID: 26732313 [TBL] [Abstract][Full Text] [Related]
26. [Bilateral ageusia caused by right thalamic infarction]. Kogawa S; Yamakawa I; Nakajima A; Yamada S Rinsho Shinkeigaku; 2013; 53(1):24-8. PubMed ID: 23328062 [TBL] [Abstract][Full Text] [Related]
27. Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics study. Maruyama D; Tobinai K; Ogura M; Uchida T; Hatake K; Taniwaki M; Ando K; Tsukasaki K; Ishida T; Kobayashi N; Ishizawa K; Tatsumi Y; Kato K; Kiguchi T; Ikezoe T; Laille E; Ro T; Tamakoshi H; Sakurai S; Ohtsu T Int J Hematol; 2017 Nov; 106(5):655-665. PubMed ID: 28664499 [TBL] [Abstract][Full Text] [Related]
28. [Stomatitis and ageusia induced by candesartan]. Chen C; Chevrot D; Contamin C; Romanet T; Allenet B; Mallaret M Nephrologie; 2004; 25(3):97-9. PubMed ID: 15185557 [TBL] [Abstract][Full Text] [Related]
29. Fatal Case of Primary Cutaneous Aggressive T-Cell Lymphoma Switching From a CD4+ to a CD8+ Phenotype: Progressive Disease With Bexarotene and Romidepsin Treatment. Johnson WT; Leeman-Neill RJ; Patel P; Ho J; Grandinetti LM; Jedrych J; Craig FE Am J Dermatopathol; 2016 Nov; 38(11):832-837. PubMed ID: 27322928 [TBL] [Abstract][Full Text] [Related]
31. Doc, I can't taste my food! Madnani NA; Khan KJ Indian J Dermatol Venereol Leprol; 2010; 76(3):296-7. PubMed ID: 20445311 [No Abstract] [Full Text] [Related]
32. Romidepsin: a novel histone deacetylase inhibitor for cancer. Bertino EM; Otterson GA Expert Opin Investig Drugs; 2011 Aug; 20(8):1151-8. PubMed ID: 21699444 [TBL] [Abstract][Full Text] [Related]
33. Romidepsin (Istodax) for cutaneous T-cell lymphoma. Med Lett Drugs Ther; 2010 May; 52(1339):42-3. PubMed ID: 20508581 [No Abstract] [Full Text] [Related]
34. Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL. Rozati S; Cheng PF; Widmer DS; Fujii K; Levesque MP; Dummer R Clin Cancer Res; 2016 Apr; 22(8):2020-31. PubMed ID: 26660520 [TBL] [Abstract][Full Text] [Related]
35. Romidepsin Therapy Over 5 Years in a Clinical Setting-Real-world Experience. Bates SE; Geskin LJ JAMA Oncol; 2016 Jun; 2(6):794-5. PubMed ID: 27054784 [No Abstract] [Full Text] [Related]
36. Romidepsin for the treatment of relapsed/refractory cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome): Use in a community setting. Reddy SA Crit Rev Oncol Hematol; 2016 Oct; 106():99-107. PubMed ID: 27637355 [TBL] [Abstract][Full Text] [Related]